New drug advancements presented at ASCO

Bookmark and Share
Published: 21 Jul 2017
Views: 1367
Dr Christian Rolfo – Antwerp University, Belgium

Dr Rolfo talks with ecancer at the Best of ASCO 2017 meeting in Miami about new drug advancements that were presented at the ASCO annual meeting. He discusses the new NTRK inhibitor, larotrectinib, which is yielding a 76% response rate and a 12% complete response rate with patients.

He goes on to talk about new combinations on the horizon for immunotherapy and drugs for a variation of tumour types.

Dr Philip talked about new drugs that are in development for pancreatic cancer here.